Markets

Pain meds biotech KemPharm sets terms for $52 million IPO

KemPharm, which is developing abuse-deterrent versions of widely-prescribed pain medications, announced terms for its IPO on Friday.

The Coralville, IA-based company plans to raise $52 million by offering 4 million shares at a price range of $12 to $14. At the midpoint of the proposed range, KemPharm would command a fully diluted market value of $207 million.

KemPharm, which was founded in 2006, plans to list on the NASDAQ under the symbol KMPH. Cowen & Company and RBC Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of April 13, 2015.

The article Pain meds biotech KemPharm sets terms for $52 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

KMPH

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More